Utility of SARC-F for Assessing Physical Function in Elderly Patients With Cardiovascular Disease

Tanaka, Shinya; Kamiya, Kentaro; Hamazaki, Nobuaki; Matsuzawa, Ryota; Nozaki, Kohei; Maekawa, Emi; Noda, Chiharu; Yamaoka‐Tojo, Minako; Matsunaga, Atsuhiko; Masuda, Takashi; Ako, Junya

doi:10.1016/j.jamda.2016.10.019

Cited by 86 publications

(70 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When looking behind the covariates, we almost mirror the results of Tanaka et al [7] , who also reported significant differences for gait speed and handgrip strength between men aged ≥ 65 years with and without sarcopenia according the SARC-F. The fact that the discriminatory power was highest for gait speed ( p < 0.001) is hardly surprising, but we also detected a significant difference for handgrip strength ( p = 0.004).…”

Section: Discussionsupporting

confidence: 87%

The SARC-F Questionnaire: Diagnostic Overlap with Established Sarcopenia Definitions in Older German Men with Sarcopenia

Kemmler

Sieber²,

Freiberger³

et al. 2017

Gerontology

View full text Add to dashboard Cite

Background: The high relevance of sarcopenia for the aging societies of most developed nations is emphasized by its recent inclusion in the ICD-10-CM (M62.84). However, diagnosing sarcopenia is a daunting task. Apart from varying definitions, the proper assessment of recognized sarcopenia criteria is time and cost consuming. A short and inexpensive screening tool may thus be welcome for clinicians and others working in the area of gerontology. Recently, a simple questionnaire was provided (SARC-F) that may adequately realize this aim. Objective: The purpose of this study is to compare established sarcopenia definitions (European Working Group on Sarcopenia in Older People [EWGSOP], Foundation National Institute of Health [FNIH], International Working Group on Sarcopenia [IWGS]) with the SARC-F. Our hypothesis was that the diagnostic overlap between the SARC-F and sarcopenia as determined by these recognized definitions was too low to reliably diagnose sarcopenia. Methods: Seventy-four community-dwelling German men aged 70 years and older with established sarcopenia according to EWGSOP and/or FNIH and/or IWGS were screened with the SARC-F questionnaire. Results: Applying the definitions of EWGSOP, IWGS, and FNIH, 66.2, 43.2, and 50% of the cohort were classified sarcopenic, respectively. The SARC-F identified 33.5% of the cohort as sarcopenic. The predictive power of the SARC-F increased when men were classified as sarcopenic according to 2 (57.1%) or all (78.8%) sarcopenia definitions. The diagnostic overlap with the 3 sarcopenia definitions varied between 38.8% (SARC-F-FNIH) and 54.1% (SARC-F-IWGS). In comparison, the overlap of diagnosed sarcopenia ranged from 27.0% (FNIH-IWGS) to 49.0% (IWGS-EWGSOP) among the definitions themselves. Only 12.2% of the men met all 3 sarcopenia definitions. Conclusion: The diagnostic overlap with respect to sensitivity of the SARC-F and present sarcopenia definitions was at least as high as the range of the diagnostic overlap of these approaches themselves. Thus, although the sensitivity of the SARC-F may be debatable, for want of a better option it seems reasonable to consider the SARC-F as a first simple step within a hierarchical screening procedure. Independently of this procedure, a universally accepted mandatory sarcopenia definition along with comprehensive criteria and fixed cutoff points should be provided promptly.

show abstract

Section: Discussionsupporting

confidence: 87%

The SARC-F Questionnaire: Diagnostic Overlap with Established Sarcopenia Definitions in Older German Men with Sarcopenia

Kemmler

Sieber²,

Freiberger³

et al. 2017

Gerontology

View full text Add to dashboard Cite

show abstract

“…Sarcopenia was associated with allcause mortality in both sexes after adjusting for potential confounders. To our knowledge, this is the first study to demonstrate the prognostic value of sarcopenia defined by muscle function and muscle mass in elderly patients Recent studies estimated the prevalence rates of sarcopenia to be approximately 1% -29% in people dwelling within the community [8-10], 10.2% -60% in hospitalized patients [11][12][13][14], and 14.3% -32.8% in those in long-term care [15,16]. A recent meta-analysis of studies in the general population, including 35 reports with a total of 58404 individuals, showed that the prevalence of sarcopenia defined by low muscle mass was 10% in both sexes [25], and the prevalence was higher for BIA-based methods than DXA-based methods (BIA: 13%, DXA: 8% in both sexes).…”

Section: Discussionmentioning

confidence: 99%

“…Depending on the diagnostic criteria used, sarcopenia has estimated prevalence rates of approximately 1% -29% in people dwelling in the community [8][9][10], 10.2% -60% in hospitalized patients [11][12][13][14], and 14.3% -32.8% in those in long-term care [15,16]. In addition, the number of patients with sarcopenia has been suggested to increase over the next 30 years [17].…”

Section: Introductionmentioning

confidence: 99%

Sarcopenia: Prevalence and Prognostic Implications in Elderly Patients with Cardiovascular Disease

Kamiya

Hamazaki²,

Matsuzawa³

et al. 2017

JCSM Clinical Reports

Self Cite

View full text Add to dashboard Cite

Aims Sarcopenia has recently been given an ICD-10 code. However, there have been no systematic investigations regarding the prevalence or prognostic value of sarcopenia in cardiovascular disease (CVD) according to the international consensus definition. The present study was performed to investigate the prevalence and prognostic value of sarcopenia in elderly patients with CVD. Methods and resultsThe study population consisted of 1603 admitted patients aged ≥ 65 years (74.4 ± 6.2 years, 1049 men) with CVD. Sarcopenia was defined according to the recommended diagnostic algorithm of the Asia Working Group for Sarcopenia. The endpoint for the study was all-cause mortality. The overall sarcopenia prevalence rate was 29.7% (19.6% in men and 48.7% in women). The prevalence rates of sarcopenia across major diagnostic categories were as follows: acute coronary syndrome, 17.8%; post-cardiac surgery, 31.8%; and heart failure, 35.2%. During the 2.3 ± 2.1-year follow-up period, 175 deaths occurred. Patients with sarcopenia showed higher risk of allcause mortality compared with non-sarcopenic patients (adjusted hazard ratio: 1.44; 95% confidence interval: 1.01 -2.05; P = 0.044).Conclusions Sarcopenia is highly prevalent among elderly patients with CVD and is associated with increased mortality risk.

show abstract

“…Patients with sarcopenia had a worse outcome. SARC-F is a rapid screen for sarcopenia which has been demonstrated to be valid and predict declining function and mortality (36)(37)(38)(39).…”

Section: Figure 2 Mechanisms Of Sarcopenia In Persons With Copdmentioning

confidence: 99%

Frailty, Comorbidity, and COPD

Charbek

Espiritu

Nayak

et al. 2018

The Journal of nutrition, health and aging

View full text Add to dashboard Cite

Utility of SARC-F for Assessing Physical Function in Elderly Patients With Cardiovascular Disease

Cited by 86 publications

References 36 publications

The SARC-F Questionnaire: Diagnostic Overlap with Established Sarcopenia Definitions in Older German Men with Sarcopenia

The SARC-F Questionnaire: Diagnostic Overlap with Established Sarcopenia Definitions in Older German Men with Sarcopenia

Sarcopenia: Prevalence and Prognostic Implications in Elderly Patients with Cardiovascular Disease

Frailty, Comorbidity, and COPD

Contact Info

Product

Resources

About